Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s EBIT?
- ImmunityBio, Inc. (IBRX) reported EBIT of -$69.79M in Q1 2026.
- How has ImmunityBio, Inc.'s EBIT changed year-over-year?
- ImmunityBio, Inc.'s EBIT decreased by 8.3% year-over-year, from -$64.43M to -$69.79M.
- What is the long-term trend for ImmunityBio, Inc.'s EBIT?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s EBIT has grown at a -6.2% compound annual growth rate (CAGR), from -$330.28M to -$256.03M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about ImmunityBio, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude